May 21 (Reuters) - French drugmaker Sanofi on

Tuesday announced it is collaborating with artificial

intelligence company OpenAI and Formation Bio to boost its drug

development projects through the use of Artificial Intelligence.

Sanofi said in a statement that the partnership with OpenAi

will allow it to access proprietary data to develop AI models

for its biopharma models, while Formation Bio will provide

additional engineering resources.

Major drugmakers are using artificial intelligence to find

patients for clinical trials quickly, or to reduce the number of

people needed to test medicines, both accelerating drug

development and potentially saving millions of dollars.